A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab
Recruiting
Observational Study
B-Cell ALL
B-Cell Acute Lymphoblastic Leukaemia
B-Cell Lymphoblastic Leukemia
B-Cell Lymphoblastic Leukemia/Lymphoma
B-cell Acute Lymphoblastic Leukemia (B-ALL)
B-cell Acute Lymphoblastic Leukemia
B-cell Childhood Acute Lymphoblastic Leukemia
B-cell Leukemia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 1 – 23
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- Arkansas Children's Hospital Research Institute · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this observational study is to establish a clear vaccination protocol for pediatric patients (less than 21 years old) who have received treatment for B-cell Acute Lymphoblastic Leukemia/Lymphoma. The main study aims are:
* Evaluate the persistence of protective immunity to routine childhood vaccinations in participants with B-ALL/Ly who have received blinatumomab.
* To determine wheth…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of B-lineage acute lymphoblastic leukemia/lymphoma
* ≥1 year old and up to 21 years old at diagnosis
* Informed consent provided, and if applicable, child assent provided
* Must have received all vaccinations routinely administered during first year of life
Exclusio…
Contacts
Stephanie Thomas, RN
501-364-3820
CONTACT